5647454 Public Hearing on B21-32, Specialty Drug Copayment Limitation Act of 2015

Council of the District of Columbia

Committee on Business, Consumer, and Regulatory Affairs

Notice of a Public Hearing

                                                                                     

John A. Wilson Building   1350 Pennsylvania Avenue, NW, Suite 119    Washington, DC 20004                                 

 

Councilmember Vincent B. Orange, Sr., Chair

Committee on Business, Consumer, and Regulatory Affairs

Announces a Public Hearing

 

 on

 

·        B21-32, the “Specialty Drug Copayment Limitation Act of 2015”

 

Wednesday, October 28, 2015, 2:00 P.M.

John A. Wilson Building, Room 500

1350 Pennsylvania Avenue, N.W.

Washington, DC 20004

 

Councilmember Vincent B. Orange, Sr., announces the scheduling of a public hearing by the Committee on Business, Consumer, and Regulatory Affairs on B21-32, the “Specialty Drug Copayment Limitation Act of 2015”.  The public hearing is scheduled for Wednesday, October 28, 2015 at 2:00 p.m. in Room 500 of the John A. Wilson Building, 1350 Pennsylvania Ave., NW, Washington, DC 20004. 

 

B21-32, the “Specialty Drug Copayment Limitation Act of 2015”, would impose a limit on the amount that an individual must pay in copayment or coinsurance through a health benefit plan for a prescription for a specialty drug.

 

Individuals and representatives of organizations who wish to testify at the public hearing are asked to contact Faye Caldwell of the Committee on Business, Consumer, and Regulatory Affairs at [phone] or by email at [e-mail] and provide their name(s), address, telephone number, email address and organizational affiliation, if any, by close of business Monday, October 26, 2015.  Each witness is requested to bring 20 copies of his/her written testimony. Representatives of organizations and government agencies will be limited to 5 minutes in order to permit each witness an opportunity to be heard. Individual witnesses will be limited to 3 minutes.

 

If you are unable to testify at the public hearing, written statements are encouraged and will be made a part of the official record. The official record will remain open until close of business Wednesday, November 11, 2015.  Copies of written statements should be submitted to the Committee on Business, Consumer, and Regulatory Affairs, Council of the District of Columbia, Suite 119 of the John A. Wilson Building, 1350 Pennsylvania Avenue, N.W., Washington, D.C. 20004.